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A proteome-wide mapping of interactions between hepatitis C virus (HCV) and human proteins was
performed to provide a comprehensive view of the cellular infection. A total of 314 protein–protein
interactions between HCV and human proteins was identified by yeast two-hybrid and 170 by
literature mining. Integration of this data set into a reconstructed human interactome showed that
cellular proteins interacting with HCV are enriched in highly central and interconnected proteins. A
global analysis on the basis of functional annotation highlighted the enrichment of cellular pathways
targeted by HCV. A network of proteins associated with frequent clinical disorders of chronically
infected patients was constructed by connecting the insulin, Jak/STAT and TGFb pathways with
cellular proteins targeted by HCV. CORE protein appeared as a major perturbator of this network.
Focal adhesion was identified as a new function affected by HCV, mainly by NS3 and NS5A proteins.
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Introduction
Hepatitis C virus (HCV) infection is characterized by a high
rate of chronicity and concerns 170 millions of individuals
worldwide. Chronically infected patients present liver injury
essentially mediated by immune mechanisms and metabolic
disorders associated with hepatic steatosis, fibrogenesis and
insulin resistance to various extent (Negro, 2006; Moradpour
et al, 2007). Long-term-infected patients have a high risk of
developing cirrhosis and hepatocarcinoma, but despite con-
siderable efforts, molecular basis of HCV pathology remains
poorly understood. HCV genome is a positive-strand RNA of
9.6 kb encoding a polyprotein that is post-translationally
processed into structural (CORE, E1, E2 and p7) and non-
structural (NS2, NS3, NS4A, NS4B, NS5A and NS5B) proteins
(Appel et al, 2006). HCV variants have been classified into six
genotypes with biological and antigenic differences. Whereas
infection by all genotypes is associated with insulin resistance
and fibrosis, a correlation between hepatic steatosis severity
and viral replication is preferentially observed for genotype 3.
Genotypic differences also correlate with interferon sensitivity,
with genotypes 2 and 3 responding better to combined
interferon and ribavirine therapy. We focused here on HCV
genotype 1b, which is associated with insulin resistance,
fibrosis, mild steatosis and poor sensitivity to treatment
(Lonardo et al, 2004; Strader et al, 2004).
The rapidly growing knowledge of protein–protein interac-
tion (PPI) networks (interactome) for human, model organ-
isms and host–pathogen begins to provide network-based
models for diseases. In a network approach, viral pathogenesis
can be viewed as the expression of new constraints on the
protein network imposed by the virus when connecting to the
cellular interactome. Identification of topological and func-
tional properties that are lost or deregulated, or that emerged
in the ‘infection network’, becomes a major challenge for a
systems understanding of viral infection (Tan et al, 2007).
High-throughput yeast two-hybrid (Y2H) screens of human
cDNA library (Calderwood et al, 2007) and computation-based
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analysis (Uetz et al, 2006) have been used previously to study
Epstein–Barr virus (EBV), Kaposi sarcoma herpes virus and
varicella zoster virus interactions with host cell factors.
Analysis of virus–human protein inter-interactome network
revealed that host interactors tend to be enriched in proteins
that are highly connected in the cellular network (Calderwood
et al, 2007; Dyer et al, 2008). These hub proteins are thought to
be essential for the normal cell functioning and during
pathogenesis.
Several laboratories have joined their efforts to develop
infection mapping project (I-MAP). The goal of I-MAP is to
provide a comprehensive view of viral infections at the protein
level by mapping the interactions of a large number of viral
proteins with host proteins. Screening and mapping have been
designed to address specific questions, such as virulence/at-
tenuation, species barrier, identification of therapeutic targets,
chronicity and the risk of cancer development.
Here, a proteome-wide mapping approach of interactions
between HCVand cellular proteins was performed to provide a
comprehensive view of viral infection (Figure 1A). A viral
ORFeome was first generated that included ORFs encoding all
full-length mature proteins and several protein domains of
genotype 1b strain (Supplementary Figure S1). These viral
baits were screened against human cDNA libraries using a
highly stringent Y2H assay (IMAP Y2H data set). Together with
interactions extensively mined and curated from the literature
(IMAP LCI data set), this comprehensive host–virus infection
network was integrated into a reconstructed human protein–
protein interactome. Analysis of the ‘infection network’
(V-HHCV; Figure 1A) revealed topological features of cellular
interactors and identified functional pathways related to viral
biology and pathogenesis.
Results and discussion
Construction of an HCV–human interactome map
A comprehensive interactome map between HCV and cellular
proteins was generated by Y2H screens. Twenty-seven
constructs encoding full-length HCV mature proteins or
discrete domains were cloned using a recombination-based
cloning system (Walhout et al, 2000) (Supplementary Figure S1).
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Figure 1 The HCV interaction network. (A) Nomenclature. V: viral protein (black node). HHCV: human protein interacting with HCV proteins (red node). HNot-HCV:
human protein not interacting with HCV proteins (blue node). V-HHCV: HCV–human protein interaction (red edge). HHCV–HHCV: interaction between HCV-interacting
human proteins (blue edge). H–H: human–human protein interaction (blue edges). V-HHCV represents the interactions between HCV and human proteins (black box).
HHCV–HHCV is composed of human proteins interacting with viral proteins (red box). H–H network represents interactions between human proteins (blue box). (B)
Number of proteins and interactions in HCV–human interaction network. Number of human proteins interacting with HCV proteins (HHCV) and corresponding number of
protein–protein interactions (V-HHCV PPI). Data are given for our yeast two-hybrid screens (IMAP Y2H) and for literature-curated interactions (IMAP LCI). (C) Validation
of Y2H interactions by co-affinity purification assay. Nine out of 22 positive co-AP assays are shown, representing the following: NS5A-SORBS2, NS3-CALCOCO2,
NS5A-BIN1, NS5A-MOBK1B, NS5A-EFEMP1, NS3-PSMB9 and NS5A-PSMB9, NS5A-PPPIRI3L, NS3-RASAL2. After pull-down with GST-tagged viral baits or with
negative-control GST alone cellular preys are identified with anti-Flag antibody. Anti-GST antibody identifies either GST-alone or GST-tagged viral baits. Expression of
cellular preys in cell lysate is controlled by anti-Flag (bottom panel). (D) Number of interactions by viral protein.
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Four independent screens were performed with each HCV
bait protein, probing two distinct human cDNA libraries, either
by mating (IMAP1 screens) or by transformation (IMAP2
screens; see Materials and methods). Fetal brain and spleen
cDNA libraries were used instead of a liver library because the
liver is known to overexpress a large number of secreted
proteins, which could interfere with the quality of the screens.
Comparing EST data from fetal brain and spleen with EST data
from liver revealed that 87% of genes expressed in the liver are
also expressed in brain or spleen (http://www.ncbi.nlm.nih.
gov/sites/entrez?db¼unigene). A total of 314 HCV–human
PPIs were identified, involving 278 human proteins (Figure 1B,
IMAP Y2H data set in Supplementary Table SI). More than
90% of the cellular interactors identified are expressed in the
liver. Pairwise interactions between HCV and human proteins
were also extracted from the literature by automatic text
mining and checked by expert curation (see Materials and
methods; IMAP LCI data set in Supplementary Table SI). A
total of 135 PPI were extracted from Pubmed and 89 were
extracted from BIND database (Bader et al, 2003) (Figure 1B).
The resulting HCV–human interactome is thus composed of
481 PPIs with 65% new interactions, involving 11 HCV
proteins and 421 distinct human proteins (Figure 1B). IMAP1
and IMAP2 screens share 22 interactions (7% of IMAP Y2H
data set). This overlap is in the range of previously reported
data using two Y2H high-throughput screening methods (Lim
et al, 2006) and suggests that despite screens characteristics,
summarized in Supplementary Table SII, saturation has not
been reached. Differences in the screening methods, such as
sensitivity of the different yeast strains to selective drugs,
differential growth rate of colonies and low penetrance of
interaction phenotype, could account for this observation. The
low redundancy between IMAP Y2H and IMAP LCI data sets
may also emphasize a high false-negative rate of the Y2H
system, which would be in agreement with recent studies
(Rual et al, 2005; Huang et al, 2007). An interesting hypothesis
is that different methods of screening may lead to the
exploration of different spaces of the HCV–human interac-
tome. As false-positives may also contribute to the weak
overlap of IMAP1 and IMAP2, two validation methods were
used to assess the confidence of the IMAP Y2H data set. Two-
thirds of the data set was retested by direct Y2H between viral
protein baits and cellular protein preys identified by our Y2H
screens (Y2H pairwise matrices). From the remaining interac-
tions, 26 PPIs (25%) were retested by co-affinity purification
and 22 PPIs could be validated (validation rate: 85%; Figure 1C
and Supplementary Table SI). This Y2H data set was thus of
very high confidence for further analysis at the topological and
functional levels. In Table I, the top 21 new interactions
validated by GST pull-down experiments and identified in one
or two screens are shown. Analysis of the HCV-infection
network (V-HHCV, Figure 1A) showed that NS3, NS5A and
CORE are the most connected proteins, with 214, 96 and 76
cellular partners, respectively, highlighting the potential multi-
functionality of these proteins during infection (Supplemen-
tary Table SI, Figure 1D). Highly interacting proteins are
known to be significantly more disordered than low-degree
(LD) proteins (Haynes et al, 2006). Interestingly, NS3, NS5A
and CORE are the only HCV proteins predicted to contain at
least one intrinsic disordered region, according to DISOPRED2
(Ward et al, 2004) (prediction of protein disorder server; data
not shown). This correlates well with the high degree (HD) of
Table I Top 21 HCV–human protein–protein interactions
HCV
protein
Human gene
name
Human protein official full name Biological process
NS3 CALCOCO2 Calcium binding and coiled-coil domain 2 May have a function in viral life cycles
NS3 EIF4ENIF1 Eukaryotic translation initiation factor 4E nuclear
import factor 1
Protein nuclear import
NS3 FRS3 Fibroblast growth factor receptor substrate 3 FGF receptor signalling pathway
NS3 CCDC21 Coiled-coil domain containing 21 Unknown
NS3 BCKDK Branched-chain ketoacid dehydrogenase kinase Branched-chain family amino-acid catabolic process
NS3 GBP2 Guanylate-binding protein 2, interferon-inducible Immune response
NS3 KPNA1 Karyopherin alpha 1 (importin alpha 5) NLS-bearing substrate import to the nucleus
NS3 PSMB9 Proteasome subunit, beta type, 9 Ubiquitin-dependent protein catabolic process
NS3 RASAL2 RAS protein activator-like 2 Regulation of small GTPase-mediated signal transduction
NS3 SMURF2 SMAD-specific E3 ubiquitin protein ligase 2 Regulation of TGFb receptor signalling pathway
NS5A EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 Integrity of fascia connective tissues
NS5A GOLGA2 Golgi autoantigen, golgin subfamily a, 2 Vesicular transport
NS5A GPS2 G protein pathway suppressor 2 JNK cascade
NS5A ITGAL Integrin, alpha L (antigen CD11A (p180), lymphocyte
function-associated antigen 1; alpha polypeptide)
Integrin-mediated signalling pathway
NS5A MOBK1B MOB1, Mps one binder kinase activator-like 1B (yeast) Cell cycle progression
NS5A NAP1L2 Nucleosome assembly protein 1-like 2 Nucleosome assembly
NS5A PPP1R13 L Protein phosphatase 1, regulatory (inhibitor) subunit 13-like Regulation of transcription, DNA-dependent
NS5A PSMB9 Proteasome subunit, beta type, 9 Ubiquitin-dependent protein catabolic process
NS5A SORBS2 Sorbin and SH3 domain containing 2 Cytoskeletal adaptor activity
NS5A TXNDC11 Thioredoxin domain containing 11 Cell redox homeostasis
NS5A VPS52 Vacuolar protein sorting 52 homolog (S. cerevisiae) Vesicular transport
HCV proteins are referenced according to their NCBI mature peptide product name (column 1). Human proteins are referenced with their cognate NCBI gene name or
their protein official full name with their main biological function (column 2, 3 and 4, respectively). The 21 interactions have been validated by GST pull-down. In the
first three entries, interactions were identified in two screens. In the rest of the entries, interactions were identified in one screen. Interaction Bin1–NS5A has been
removed from this list as already described in literature.
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these proteins. In addition, 45 cellular proteins are targeted by
more than one viral protein, suggesting their essentiality for
virus biology (Calderwood et al, 2007) (Supplementary Table
SIII).
A human PPI network (H–H network; Figure 1A) was
reconstructed from eight databases (Gandhi et al, 2006) (see
Materials and methods). This network is composed of 44 223
non-redundant PPIs between 9520 different proteins
(Figure 2A, complete list of PPIs in Supplementary Table
SIV), corresponding to 30% of the human proteome (the
remaining proteins have no known cellular partners and can
therefore not be included in this network). Interestingly,
human proteins targeted by HCV (HHCV) are clearly over-
represented in this H–H network (IMAP Y2H data set: 76%;
and IMAP LCI data set: 88%, exact Fisher test, P-value
o2.21016). This suggests that HCV preferentially targets
host proteins already known to be engaged in protein–protein
interactions (Rual et al, 2005; Stelzl et al, 2005). For the IMAP
LCI data set, the higher percentage of HHCV integrated in the
human interactome may be explained by inspection bias of
well-studied proteins and biological pathways. Analysis of
HHCV–HHCV subnetwork (all connected HHCV proteins) showed
that cellular proteins interacting with HCV are significantly
more interconnected than expected for random subnetworks
(Figures 1A and 2B, Supplementary methods). Indeed, the 338
HHCV integrated into the human interactome are distributed
into 131 connected components (versus 276 expected by
random subnetworks; z-score-based test P-value o1010,
Supplementary Table SV). The largest one is composed of
196 HHCV (versus 18 expected by random subnetworks; z-test,
P-valueo1010) and 127 are disconnected proteins. The three
remaining connected components comprised two proteins.
Two contained functionally related proteins (CLEC4M and
CD209 are lectins involved in viral entry (Lozach et al, 2003);
MVP and PARP4 are involved in Vault complex (Kedersha and
Rome, 1986)) and one contained proteins not known to be
functionally linked (KIAA1549 and CADPS).
Topological analysis of the HCV–human
interaction network
To assess how HCV proteins interplay with the cellular protein
network, we next focused on the centrality measures of HHCV
proteins integrated into the H–H interactome. Local (degree)
and global (shortest path length and betweenness) centrality
measures were calculated. Briefly, the degree (k) of a protein in
a network corresponds to its number of direct partners and is
therefore a measure of local centrality. Betweenness (b) is a
global measure of centrality, as it measures the number of
shortest paths (the minimum distance between two proteins in
the network, l) that pass through a given protein. To provide an
unbiased analysis, calculations were done on the basis of the
213 HHCV from the IMAP Y2H data set integrated in the human
interactome. The average degree, betweenness and shortest
path length of the H–H network are 9.3, 1.6104 and 4.04,
NS3
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Figure 2 Graphical representation of the HCV–human interaction network. (A) Graphical representation of H–H network. Each node represents a protein and each
edge represents an interaction. Red and blue nodes are HHCV and HNot-HCV, respectively. (B) Graphical representation of V–HHCV interaction network. Black node: viral
protein; red node: human protein; red edge: interaction between human and viral proteins (V–HHCV); blue edge: interaction between human proteins (HHCV–HHCV). The
largest component containing 196 proteins is represented in the middle of the network. Names of cellular proteins belonging to the three other connected components
are also represented.
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respectively, which is in good agreement with previous reports
(Ramirez et al, 2007) (Figure 3A). As the distribution of
properties such as node degree and node betweenness in PPI
networks appear to follow a power law, summarizing values
by their distributions appears more appropriated for compara-
tive analysis (Goh et al, 2002; Joy et al, 2005). The degree
distribution of HHCV and of the human interactome are
significantly distinct (U-test P-valueo103), with an average
degree of HHCV higher than the average degree of the human
interactome (15.6 versus 9.3). The comparison of degree
probability distribution reveals that HHCV are preferentially
represented in all class above the mean degree (Figure 3B,
left). This indicates that HCV proteins have a strong tendency
to interact with highly connected cellular proteins. However,
as degree measures only local connectivity of proteins, global
characteristics that could reflect information exchange and
propagation in the network were investigated (Hernandez
et al, 2007). At a global scale, the betweenness distribution of
HHCV and of the human interactome are significantly distinct
(U-test P-valueo103), with an average betweenness of HHCV
higher than the average betweenness of the human inter-
actome (3.8104 versus 1.6104). As for the degree, the
comparison of betweenness probability distribution shows an
excess of HHCV in all class above the mean betweenness
(Figure 3B, right). In addition, the shortest path length
distribution of HHCVand of the human interactome were found
significantly distinct (U-test P-valueo105), with an average
shortest path length of HHCV lower than average shortest path
length of the human interactome (3.50 versus 4.04) revealing
the topological proximity of HHCV. Both local and global
centrality of HHCV from the IMAP LCI data set were higher than
for the IMAP Y2H data set, emphasizing the problem of
literature inspection bias and reinforcing the unbiased
approach of Y2H screening (Supplementary Table SV). To
ensure that the preferential attachment to central HHCVwas not
due to inherent bias associated to false positive in the H–H
interactome, we performed the same analysis with a high-
confidence, but less comprehensive, human interactome
(Supplementary Table SV). This trend was maintained with
this data set, confirming that HHCVare highly central within the
human interactome, both locally and globally, and appear
relatively close to each other in this network. For comparative
analysis of HCV and EBV, the centrality measures were also
computed for HEBV (data set from Calderwood et al (2007).
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Figure 3 Topological analysis of the HCV–human interaction network. (A) Topological analysis of H and HHCV in H–H network. Average values of degree (k),
betweenness (b) and shortest path length (l) for all human proteins and for HHCV from the IMAP Y2H data set. (B) Degree and betweenness distribution of H and HHCV
proteins in H–H network. P(k) is the probability of a node to connect k other nodes in the network. P(b) is the probability of a node to have a betweeness equal to b in the
network. Normalized log degree (left) and log betweenness (right) distribution of H (blue) and HHCV proteins (red). Solid line represents linear regression fit. Vertical
dashed lines give mean degree and betweenness values. Each class is represented with conventional standard error. (C) Degree and betweenness correlation of H in
H–H network. Normalized log degree (x axis) and log betweenness (y axis) of H proteins into H–H network. Black solid line represents the linear regression fit (R2¼0.56).
Horizontal and vertical dashed lines give the mean degree and betweenness values, respectively. Low-degree (LD) and high-degree (HD) classes were defined by using
the average degree cutoff. (D) Mean degree and betweenness of HNot-HCV and HHCV for LD and HD proteins. Top: mean betweenness (log scale) of HNot-HCV (blue) and
HHCV (red) is given for LD and HD classes. Bottom: mean degree of HNot-HCV (blue) and HHCV (red) is given for LD and HD classes. The conventional standard error
threshold and the U-test P-value are represented (***P-value o1010, NS: not significant).
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Degree, betweenness and shortest path followed the same
tendency with HEBV proteins (Supplementary Table SV and
Supplementary Figure S2) and were in good agreement with a
previous report (Calderwood et al, 2007). These results
indicate that preferential attachment on central proteins may
be a general hallmark of viral proteins as recently suggested by
analysis of the literature (Dyer et al, 2008). The high centrality
of proteins was previously shown to correlate with their
functional essentiality for the yeast model organism (Jeong
et al, 2001; Ekman et al, 2006). In mammals, lethal and
disease-related proteins were found enriched in central
proteins (Wachi et al, 2005; Stark et al, 2006; Goh et al,
2007; Hernandez et al, 2007). This suggests that HCV proteins
interacted with essential proteins in the cell.
To determine which of the degree or the betweenness most
influences the probability of interaction between viral and
cellular proteins, we used a generalized linear model to test the
separate and additive effects of both measures (Supplementary
methods). This analysis revealed that betweenness better
explains the probability of interaction between viral and
human proteins (ANOVA P-value o103). Figure 3C shows a
partial correlation between k and b centrality measures
(R2¼56%, P-valueo1016), explained by the high variability
of betweenness at LD values. We thus asked whether this high
variability observed at LD could explain the preponderant
effect of betweenness. For this purpose, the data sets were split
in LD and HD protein classes according to the average degree
of the human interactome. For cellular proteins included in LD
class, HCV interacts preferentially with proteins of high-
betweenness independently of their degree property
(Figure 3D). Within the HD class, interaction with HCV
proteins is dependent on both betweenness and degree of
cellular proteins. On the basis of a recent study in yeast (Joy
et al, 2005), it can be extrapolated that LD high-betweenness
HHCV proteins could exert an effect as connectors or bottle-
necks between cellular modules and may thus be essential for
the infection.
Functional analysis of the HCV–human interaction
network
To better understand biological functions targeted by HCV, we
next tested the enrichment of specific pathways for all
interactors of a given viral protein. This was done by analysing
the HHCV proteins with regard to the KEGG functional
annotation pathways (Table II, Materials and methods).
Although this approach is not totally unbiased because
functions have not yet been attributed to all proteins, it
remains a powerful way of incorporating conventional biology
in system-level data sets. This analysis showed enrichment for
three pathways associated with HCV clinical syndromes
(insulin, TGFb and Jak/STAT pathways) and identified focal
adhesion as a novel pathway affected by HCV.
IJT network (insulin–Jak/STAT–TGFb network)
Chronic infection by HCV is associated with an increased risk
for metabolic disorders with the development of steatosis.
Insulin resistance is a common feature of this process. It also
contributes to liver fibrosis and is a predictor of a poor
response to interferon-a (IFN-a) anti-viral therapy (D’Souza
et al, 2005; Romero-Gomez et al, 2005). Conversely, IFN-a can
prevent fibrosis progression (Poynard et al, 2002). TGFb has a
crucial function in maintaining cell growth and differentiation
in the liver. It is a strong profibrogenic cytokine whose
production is frequently enhanced during infection. Impaired
TGFb response is also observed during HCV infection
(Schuppan et al, 2003). Although insulin, TGFb and Jak/
STAT pathways have been suspected to be involved in these
clinical features (Romero-Gomez, 2006), their closely related
perturbation during HCV infection remains largely unex-
plained. We thus used a network approach to identify cellular
proteins targeted by HCVand localized at the interface of these
pathways. The resulting interaction map was constructed to
form the IJT network (insulin–Jak/STAT–TGFb network,
Table II KEGG pathway enrichment for HHCV
KEGG name CORE E1 E2 NS3 NS5A NS5B
Cell–cell and cell–ECM interactions
Adherens junction 5 6 (5)
Cell communication 6 (2) 8 (8)
Cell adhesion molecules (CAMs) 3 (1)
ECM–receptor interaction 2 (1) 6 (6)
Focal adhesion 10 (9) 8 (2)
Gap junction 4
Tight junction 2
Signalling pathways
TGFb signalling pathway 4
Jak-STAT signalling pathway 6 3
Adipocytokine signalling pathway 5
MAPK signalling pathway 3(2)
Phosphatidylinositol signalling system 2 4
Wnt signalling pathway 7 (3)
Insulin signalling pathway 3
B cell receptor receptor signalling pathway 3
T cell receptor signalling pathway 5
Over-represented KEGG pathways were identified after multiple testing adjustments (adjusted P-valueo5102) and are listed by viral protein. For each pathway,
number of HHCV is given, with the relative contribution of IMAP Y2H dataset in brackets. Shaded entries denote discussed pathways.
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Figure 4A; Supplementary methods). Sixty-six HHCV proteins
are connecting two pathways, whereas 30 HHCV proteins are
connecting the three pathways. Interaction of these proteins
with HCV proteins may thus induce functional perturbations
that could expand to adjacent pathways. One of these proteins
is PLSCR1 (Scramblase 1), connecting insulin and Jak/STAT
pathways. Known to be involved in the redistribution of
plasma membrane phospholipids (Sahu et al, 2007), this
protein is also a potential activator of genes in response to
interferon, and its knockdown with siRNA favours viral
replication (Dong et al, 2004). Interestingly, PLSCR1/ mice
also exhibit an onset of insulin resistance (Wiedmer et al,
2004). Although not annotated in the insulin or Jak/STAT
pathways, PLSCR1 thus appears essential for the functionality
of these pathways. By interacting with PLSCR1, CORE could
therefore interfere with both Jak/STAT and insulin pathways.
Another example is the nuclear factor Yin Yang 1 (YY1), which
exhibits a more central position in the IJT network as it
connects the three pathways. HCV CORE interaction with YY1
has been previously shown to be functional relieving NPM1
expression. This observation could be extrapolated to PPARd
expression and SMADs transcriptional activity in support of
insulin and TGFb pathway modulation (Kurisaki et al, 2003;
Mai et al, 2006; He et al, 2008). Interestingly, BCL6, targeted by
NS5A, is another transcriptional repressor at the interface of
the three pathways that inhibit Smad signalling (Wang et al,
2008). It also exerts an effect as a corepressor of PPARd
(Lee et al, 2003) and it regulates the expression of a subset
of Jak/STAT pathway target genes (Arbouzova et al, 2006).
Thus, perturbation of these pathways can reasonably be
expected as a consequence of BCL6 or YY1 targeting by
HCV. Also central in the IJT network, NOTCH1 has been
reported to interfere functionally with the three pathways.
Literature analysis revealed that many of the proteins
at the interface are actually known to have an important
function in the regulation of one, two or the three pathways
without being annotated in the KEGG database. These are only
illustrative examples of cellular targets most likely to be
involved in HCV-induced phenotypes. Although this molecu-
lar approach of the pathology is applicable to basal element of
a system (proteins in this work) some of the clinical
phenotypes observed in chronic HCV infection are most likely
NS3
NS5A
CORE
NS5B
E2
P7
E1
F
NS2
NS4A
NS4B
51.3% 
in IJT 
network
44.5%
NS3
20%
NS5A
15.8%
CORE
26.6%
NS3
22.4%
NS5A
27.7%
CORE
Jak/STAT pathway
Insulin pathway
TGFβ pathway
Insulin and Jak/STAT
Jak/STAT and TGFβ
Insulin and TGFβ
HHCV IMAP LCI
HHCV IMAP Y2H
Figure 4 IJT network. (A) Graphical representation of IJT network. Protein (nodes) members of insulin (blue), Jak/STAT (red) and TGFb (green) pathways according
to KEGG annotation, and their interactions (edges) are shown (proteins interacting with HCV proteins are named). Proteins shared by two pathways are shown in
secondary colours (pink, yellow and cyan). Grey and black nodes are neighbours that connect the KEGG pathways and that interact with HCV proteins (grey: protein
from the IMAP Y2H data set; black: protein from the IMAP LCI data set). Neighbours interacting with HCV but not connecting the KEGG pathways are not represented.
Discussed protein examples PLSCR1 and YY1 are in box. References to visualization tools are provided in supplementary files (network visualization). IJT network
construction in Supplementary methods. (B) Relative contribution of each viral protein in V–HHCV. Percentage interactions for the three most interacting viral proteins,
relative to the total number of interactions as listed in Supplementary Table SI, are shown. A total of 51.3% of CORE interactions are concentrated in the IJT network.
(C) Relative contribution of each viral protein in IJT network. Percentage interactions for the three most interacting viral proteins, relative to the total number of viral
protein interactions with proteins of IJT network, are shown.
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to result from the integrative effect of protein interactions
depicted in the IJT network. In addition, the robustness
property of a network can confer its ability to remain
functional in face of different perturbations despite the
deregulation of a single protein.
Another issue that became apparent in the IJT network is
that CORE protein mediates proportionally more interactions
than the other HCV proteins (Figure 4B and C). Indeed,
preferential interaction with IJT network was observed only
with CORE (51.3%, Supplementary Table SVI). As a conse-
quence, CORE makes 27.7% of the interactions in the IJT
network, corresponding to a significant enrichment (exact
Fisher test P-value o104). More precisely, this CORE’s
interactors are over-represented in Jak-STAT and TGFb path-
ways (exact Fisher test P-valueo0.05) and in HHCV connecting
insulin–Jak/STAT and insulin–TGFb pathways (exact Fisher
test P-value o0.05, Supplementary Table SVI). CORE thus
appears as a major perturbator of the IJT network. Interest-
ingly, transgenic mice expressing CORE develop insulin
resistance (Shintani et al, 2004; Pazienza et al, 2007). A
proposed mechanism was that CORE-induced SOCS3 pro-
motes proteasomal degradation of IRS1 and IRS2 through
ubiquitination (Kawaguchi et al, 2004). As SOCS3 is also a
negative regulator of Jak/STAT pathway, this could explain the
occurrence of IFN-a resistance. Clearly, the IJT network
indicates that the action of CORE is most likely to be much
more complex that previously thought. Although the IJT
network cannot yet be analysed dynamically, it remains that it
provides a unique way of deciphering some of the complex
disorders associated with chronicity. It is also worth consider-
ing that the IJT network may identify a series of genes involved
in diseases, such as steatosis and fibrogenesis, in the absence
of viral infection.
Focal adhesion
Focal adhesion was over-represented as a new function
targeted by NS3 and NS5A proteins, with a major contribution
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Figure 5 Interaction of HCV with focal adhesion. (A) Schematic representation of focal adhesion adapted from KEGG (ID: Hs04510). Proteins targeted by CORE,
NS5A and NS3 HCV proteins are shown in yellow, red and green, respectively. ECM is a generic term for proteins of the extracellular matrix, some of which are
targeted by HCV proteins (orange). (B) Functional validation of focal adhesion perturbation by NS3 and NS5A. Ninety-six-well plates were coated with fibronectin
(left) or poly-L-lysine (right) at various concentrations. The 293T cells expressing NS2, NS3, NS3/4A or NS5A were plated on the matrix for 30 min. Adherent cells were
stained with crystal violet. FA50 is the matrix concentration for half maximum adhesion. Values represent means of triplicate with standard deviation. *Student’s t-test
P-value o0.05.
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of data generated by IMAP Y2H screens (Table II). Integrin-
linked focal adhesion complexes control cell adhesion to
extracellular matrix (ECM) and association of these complexes
with actin-cytoskeleton has an important function in
cell migration. Upon binding to the ECM, both a and b
integrin subunits recruit proteins establishing a physical
link between the actin-cytoskeleton and signal transduction
pathways. When deregulated, this functional process can
lead to perturbation of cell mobility, detachment from the
ECM and tumour initiation and progression. Figure 5A shows
KEGG focal adhesion pathway with proteins targeted by
HCV, mainly NS3 and NS5A proteins. Impact of single
expression of NS3, NS3/4A or NS5A on focal adhesion
functionality was assessed using a cellular adhesion assay
on fibronectin and poly-L-lysine. These viral proteins signifi-
cantly inhibited cell adhesion to fibronectin compared
with NS2-expressing cells (an HCV protein with no interactor
in the focal adhesion pathway) or mock-transfected cells,
with 40% increase of FA50 (matrix concentration for half
maximum adhesion) (Figure 5B left, Student’s t-test P-value
o0.05). By contrast, adhesion to poly-L-lysine, which does not
engage integrins, was not affected (Figure 5B right). The same
inhibition level was observed for NS3/4A and NS3, suggesting
that the enzyme activity of this protease does not have a major
effect on focal adhesion perturbation. In addition to initiation
and progression of cancer, the engagement of focal adhesion
by HCV could have consequences on viral spreading.
Interference with several steps of the actin-cytoskeleton
remodelling has been described for retroviruses, which can
exploit this process to surf along cellular protrusions of target
cells to reach the entry site (Lehmann et al, 2005). It is
conceivable that a related process, involving binding of the
viral envelop to integrins, could be exploited by HCV to favour
its transmission. This intriguing hypothesis will, however, be
difficult to test until an efficient infection system of polarized
cell is available.
Conclusion
In a network approach of HCV infection, the interaction map
identifies all connections potentially needed for the virus to
replicate and escape host defence. Whether all interactions
really occur and have functional consequences is the open
question of all interactome studies. The answer to this
question necessitates the integration of system-level data sets
of different origins that will set the stage for complex systems
analysis of the infection. In a complex biological system,
function cannot be predicted without understanding the
component parts and their interactions and will result from
the combination of theoretical knowledge of the cellular
network with biological measurement of the interactions.
Biological measurement, however, is still in the realm of low-
throughput biology and needs major experimental improve-
ment before prediction becomes the rule rather than the
exception. Another fascinating challenge of this approach is to
identify molecular signatures common to several viruses at the
protein network level to develop original large-spectrum anti-
viral molecules. A major step towards this goal is the high-
throughput screening of a large variety of viruses, which is the
aim of I-MAP.
Materials and methods
Construction of the HCV ORFeome
All HCV protein sequences were cloned in full length and domains
except NS4B, for which no domain has been designed, using the
euHCVdb facilities (http://euhcvdb.ibcp.fr; Combet et al, 2007)
(Supplementary Figure S1). NS4A–NS3 fusion protein, as well as
NS4A–NS3 protease domain were constructed (Kim et al, 1996; Taremi
et al, 1998). All 27 ORFs from the HCV genotype 1b, isolate con1
(AJ238799) (Lohmann et al, 1999), were cloned in a Gateway
recombinational cloning system (Walhout et al, 2000). Each ORF
was PCR-amplified (with KOD polymerase, Novagen) using attB1.1
and attB2.1 recombination sites fused to forward and reverse primers,
then cloned into pDONR223 (Rual et al, 2004). All entry clones were
sequence-verified.
Yeast Two-hybrid (Y2H) screens
HCV ORFs were transferred from pDONR223 into bait vector (pPC97)
to be expressed as Gal4–DB fusions in yeast. Two different screening
methods were used (IMAP1 and IMAP2). For IMAP1, bait vectors were
introduced in MAV203 yeast strain, and both human spleen and fetal
brain AD-cDNA libraries (Invitrogen) were screened by transformation
as described (Li et al, 2004). All primary positive clones (selected on
SDWLHþ 3AT) were tested by further phenotypic assay using
two additional reporter genes: LacZ (X-Gal colorimetric assay) and
URA3 (growth assay on 5-FOA supplemented medium). Positive
clones that displayed at least two out of three positive phenotypes were
retested in fresh yeasts: bait vectors were retransformed into MAV203
and each prey cDNA (obtained by colony PCR, see below) were
transformed in combination with linearized prey vector (gap repair;
Walhout and Vidal, 2001). Clones that did not retest were discarded.
AD-cDNA were PCR-amplified and inserts were sequenced to identify
interactors. IMAP2 screens were performed by yeast mating, using
AH109 and Y187 yeast strains (Clontech; Albers et al, 2005). Bait
vectors were transformed into AH109 (bait strain), and human spleen
and fetal brain AD-cDNA libraries (Invitrogen) were transformed into
Y187 (prey strain). Single bait strains were mated with prey strain,
then diploids were plated on SDWLHþ 3AT medium. Positive
clones were maintained onto this selective medium for 15 days to
eliminate any contaminant AD-cDNA plasmid (Vidalain et al, 2004).
AD-cDNAs were PCR-amplified and inserts were sequenced.
Text-mining of interactions between HCV
and human proteins
Literature-curated interactions (LCI), describing binary interactions
between cellular and HCV proteins, were extracted from BIND
database and PubMed (publications before August 2007) by using an
automatic text-mining pipeline completed by expert curation process.
For the text-mining approach, all abstracts related to ‘HCV’ and
‘protein interactions’ keywords were retrieved, subjected to a
sentencizer (sentence partition) and a part-of-speech tagger for gene
name (based on NCBI gene name and aliases) and interaction verbs
(Rebholz-Schuhmann et al, 2008) (interact, bind, attach and so on).
Sentences presenting co-occurrences of at least one human gene name,
one viral gene name and one interaction term were prioritized to
curation by human expert.
Validation by co-affinity purification
Cellular ORFs (interacting domains found in Y2H screens) were cloned
by recombinational cloning from a pool of human cDNA library or the
MGC cDNA plasmids using KOD polymerase (Toyobo) into pDONR207
(Invitrogen). After validation by sequencing, these ORFs were
transferred into pCi-neo-3 FLAG gateway-converted. HCV ORFs
were transferred into pDEST27 (GST fusion in N-term). A total of
4105 HEK-293Tcells were then co-transfected (6ml JetPei, Polyplus)
with 1.5mg of each pair of plasmid. Controls are GST-alone against
3 FLAG-tagged prey. Two days after transfection, cells were
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harvested and lysed (0.5% NP-40, 20 mM Tris–HCl (pH 8.0), 180 mM
NaCl, 1 mM EDTA and Roche complete protease inhibitor cocktail).
Cell lysates were cleared by centrifugation for 20 min at 13 000 r.p.m. at
41C and soluble protein complexes were purified by incubating 300 mg
of cleared cell lysate with 40ml glutathione sepharose 4B beads (GE
Healthcare). Beads were then washed extensively with lysis buffer and
proteins were separated on SDS–PAGE and transferred to nitrocellulose
membrane. A total of 50mg of cleared cell lysate was analysed by
western blot to check the amount of 3 FLAG-tagged cell protein.
GST-tagged viral proteins and 3  FLAG-tagged cellular proteins were
detected using standard immunoblotting techniques using anti-GST
(Covance) and anti-FLAG M2 (Sigma) monoclonal antibodies.
Integrated human interactome network
(H–H network)
Only physical and direct binary protein-protein interactions were
retrieved from BIND (Bader et al, 2003), BioGRID (Stark et al, 2006),
DIP (Xenarios et al, 2002), GeneRIF (Lu et al, 2007), HPRD (Peri et al,
2004), IntAct (Kerrien et al, 2007), MINT (Chatr-aryamontri et al,
2007) and Reactome (Vastrik et al, 2007). NCBI official gene names
were used to unify protein ACC, protein ID, gene name, symbol or alias
defined in different genome reference databases (i.e ENSEMBL,
UNIPROT, NCBI, INTACT, HPRD and so on) and to eliminate
interaction redundancy due to the existence of different protein
isoforms for a single gene. Thus, the gene name was used in the text to
identify the proteins. Finally, only non-redundant protein–protein
interactions were retained for building the human interactome data
set.
Topological analysis
The R (http://www.r-project.org/) statistical environment was used to
perform statistical analysis and the igraph R package (http://
cneurocvs.rmki.kfki.hu/igraph/) to compute network connected
components, centrality (degree, betweenness) and shortest path
measures.
The Wilcoxon–Mann–Whitney rank sum test (the U-test) was
chosen to statistically challenge observed differences. The U-test is a
non-parametric alternative to the paired Student’s t-test for the case of
two related samples or repeated measurements on a single sample. The
generalized linear model and ANOVA analysis was used to respectively
model and test the separate and additive effects of degree and
betweenness on the probability that HCV proteins interact with human
proteins.
Functional analysis using KEGG annotations
Cellular pathway data were retrieved from KEGG (Aoki-Kinoshita and
Kanehisa, 2007) and the Kyoto Encyclopedia of Genes and Genomes
(http://www.genome.jp/kegg/) and were used to annotate NCBI gene
functions. For each viral–host protein interactors, the enrichment of
specific KEGG pathway was tested by using an exact Fisher test
(P-value o5 102) followed by the Benjamini and Hochberg multiple
test correction (Benjamini et al, 2001) to control false discovery rate.
Cell-adhesion assay
Serial dilutions (from 20 to 0.04 mg/ml) of fibronectin or poly-L-lysine
in PBS were coated on 96-well microplates overnight at 41C. Non-
specific binding sites were saturated at room temperature with PBS 1%
BSA for 1 h. HEK 293T cells were transfected with pCi-neo-3 FLAG
NS2, NS3, NS3/4A or NS5A (JetPei, Polyplus), collected 2 days later
with 2 mM EDTA in PBS, spread in triplicate at 1105 cell per well in
serum-free medium with 0.1% BSA and incubated for 30 min at 371C.
Non-adherent cells were washed away and adherent cells were fixed
with 3.7% paraformaldehyde. Cells were stained with 0.5% crystal
violet in 20% methanol for 20 min at room temperature and washed
five times in H2O. Staining was extracted from 50% ethanol in 50 mM
sodium citrate, pH 4.5, and the absorbance was read at 590 nm on an
ELISA reader (MRX microplate reader, Dynatech Laboratories). Values
were normalized to 100% adhesion at 10mg/ml. The percentage of
adhesion was determined for each cell type at each matrix concentra-
tion. 50% of maximum adhesions (FA50) were calculated from the
curves (Supplementary Figure S3) (adapted from Miao et al, 2000).
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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